Results 271 to 280 of about 31,156,887 (403)

Factors influencing adherence of group B streptococci to human vaginal epithelial cells

, 1979
Sam M. Zawaneh, Elía M. Ayoub, H Baer, Ana Cecília Ribeiro Cruz, William N. Spellacy   +4 more
openalex   +1 more source

Immunofluorescent Detection of Human B Cell Alloantigens on S-Ig-Positive Lymphocytes and Epidermal Langerhans Cells [PDF]

, 1978
Georg Stingl, Stephen I. Katz, Leslie D. Abelson, Dean L. Mann   +3 more
openalex   +1 more source

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

Genetic Control of B Cell Activation by Bacterial Lipopolysaccharide Is Mediated by Multiple Distinct Genes or Alleles [PDF]

, 1976
L. Michael Glodé, David L. Rosenstreich
openalex   +1 more source

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

Molecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon, Moa Stenudd, Margherita Zamboni, Kanar Alkass, Carl‐Johan Eriksson, Lars Pedersen, Alrik Schörling, Anna Thoss, Anders Bergh, Pernilla Wikström, Hans‐Olov Adami, Henrik Toft Sørensen, Henrik Druid, Jonas Frisén   +13 more
wiley   +1 more source

Multiparametric Optimization of Human Primary B-Cell Cultures Using Design of Experiments. [PDF]

Scand J Immunol
Rovsing AB, Green K, Jensen L, Nielsen IH, Mikkelsen JG, Degn SE.   +5 more
europepmc   +1 more source

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

Molecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček   +14 more
wiley   +1 more source

FcRL1, a New B-Cell-Activating Co-Receptor. [PDF]

Int J Mol Sci
Chen Z, Miao C, Zhang Y, Huang J, Sun Y, Chen J, Sun J, Shi W, Wang X, Wang R, Li Y, Zhao X.   +11 more
europepmc   +1 more source

Association of high‐dose radioactive iodine therapy with PPM1D‐mutated clonal hematopoiesis in older individuals

Molecular Oncology, EarlyView.
In thyroid cancer patients, high‐dose (≥7.4 GBq) radioactive iodine therapy (RAIT) was associated with a higher prevalence of clonal hematopoiesis (variant allele frequency >2%) in individuals aged ≥50 years (OR = 2.44). In silico analyses showed that truncating PPM1D mutations conferred a selective advantage under these conditions.
Jaeryuk Kim, Sungwoo Bae, Jaeyong Choi, Sun‐Wha Im, Bukyoung Cha, Gyeongseo Jung, Sun Wook Cho, Eul‐Ju Seo, Young Ah Lee, Jin Chul Paeng, Young Joo Park, Jong‐Il Kim   +11 more
wiley   +1 more source

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

New England Journal of Medicine, 2004
J. Edwards, L. Szczepanski, J. Szechiński, A. Filipowicz-Sosnowska, P. Emery, D. Close, R. Stevens, T. Shaw   +7 more
semanticscholar   +1 more source